HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A4043 Cova322 (Anti-IL-17 & TNF-Alpha) Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.
A4044 Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A4045 Odronextamab (Anti-CD20 & CD3) Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.
A4046 Ozoralizumab (Anti-TNF-α) Ozoralizumab is a humanized trivalent, bispecific NANOBODY® targeting TNFα with two anti-TNFα domains and an anti-HSA domain. It demonstrates strong anti-arthritis efficacy in human TNF transgenic mice, effective both at arthritis onset and during secondary failure of anti-TNFα IgG therapy. M.W 38.44 kDa.
A4048 Afm24 (Anti-EGFR & Fc-gamma-RIIIA) Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.
A4049 Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa.
A4051 Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4052 Faricimab (Anti-Angiopoietin 2 & VEGF-A) Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa
A4053 Reozalimab(Ibi318) (Anti-PD-1 & PD-L1) Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa
A4054 Ivonescimab (Anti-PD-1 & VEGF) Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa
A4055 Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A4056 Navicixizumab (Anti-DLL4 & VEGF) Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa
A4057 Apv-527 (Anti-4-1BB & 5T4) APV-527 is a bispecific antibody targeting 4-1BB on T-cells and the 5T4 tumor antigen to stimulate immune responses against solid tumors. It is being developed for advanced solid tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, with positive safety and efficay. M.W 157.94 kDa
A4058 Zanidatamab (Anti-HER2(ECD2&ECD4)) Zanidatamab is a humanized bispecific IgG1 monoclonal antibody targeting two non-overlapping epitopes of HER2 (ECD2 and ECD4), with immunomodulating and antineoplastic activities. It has shown anti-tumor activity across various solid tumors with HER2 expression or amplification. M.W 148.28 kDa
A4059 Tebotelimab (Anti-LAG-3 & PD-1) Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa
A4060 Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A4061 Emicizumab (Anti-Factor IX & Factor X) Emicizumab is a recombinant, humanized, bispecific antibody that binds Factor IXa and Factor X to mimic Factor VIII function. It is used to treat hemophilia A. M.W 146.82 kDa
A4062 Nivatrotamab (Anti-CD3 & GD2) Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa
A4063 Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa
A4064 Vanucizumab (Anti-Angiopoietin 2 & VEGF) Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa